Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc., a clinical-stage biopharmaceutical company, is developing targeted therapies that have shown promising potential for treating oncogene-driven non-small cell lung cancer (NSCLC), with projected peak revenues exceeding $3.6 billion. The company’s candidates, NVL-520 and NVL-655, have demonstrated deep and durable antitumor responses and improved tolerability, indicating potential shifts in treatment paradigms and market expansion opportunities. Additionally, advancements in ROS1 detection methods may enhance market penetration for these therapies, further strengthening the revenue outlook as patient activity and treatment durations are expected to improve significantly.

Bears say

Nuvalent Inc is facing a negative outlook due to significant concerns regarding its product candidates' safety profiles and potential efficacy, particularly highlighted by adverse events linked to its therapies and a less robust data profile than previously indicated. The possibility of delayed trial enrollments, negative readouts, and adverse regulatory outcomes adds further uncertainty to the company's commercialization efforts and market position. Additionally, challenges such as competition and the company's ability to secure adequate funding for ongoing research present substantial risks that may hinder Nuvalent's future growth and success in the biopharmaceutical landscape.

Nuvalent (NUVL) has been analyzed by 15 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 15 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $135, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $135, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.